Honored to present today at ESCMID Global in Vienna: Ibrexafungerp salvage results from 233 patients in the FURI study — showing high success rates! 🔬💪 A promising new tool in the antifungal pipeline. #ESCMID2025 #FURIstudy #Ibrexafungerp #Antifungals #InfectiousDiseases

#ibrexafungerp really helped a few of my patients before it was recalled. (requires good insurance and authorization, which doesn’t always go through; monthly maintenance much harder to get approved than a one time).